Diabetic neuropathic pain field presents significant opportunity for drug developers, says GlobalData
36.4% of patients with diabetic neuropathic pain in 2021 were completely treatment refractory and would benefit from new treatment options.
36.4% of patients with diabetic neuropathic pain in 2021 were completely treatment refractory and would benefit from new treatment options.
China is now focusing on establishing volume and enhancing capabilities for innovative high value drug production
48-week data from MOMENTUM phase III clinical trial show momelotinib maintained total symptom response
GlobalData predicts the average prices of dual chamber pacemakers in both India and China are expected to reduce at an average CAGR of -3.42% from 2022 to 2025.
Patients receiving Polivy plus R-CHP for DLBCL reported similar health-related quality of life outcomes
The use of procalcitonin testing for sepsis management is highest in the US
Presentations include new data on investigational medicines – favezelimab (MK-4280), zilovertamab vedotin (MK-2140) and nemtabrutinib – as well as KEYTRUDA (pembrolizumab) in multiple blood cancers
Antibody levels remained above baseline six months after completion of a three-dose (Month 0-2-6) or a two-dose (Month 0-6) vaccination schedule
The only definitive way to diagnose and stage lung cancers is through biopsies
Subscribe To Our Newsletter & Stay Updated